Vera Therapeutics (VERA)
Sells TRUTAKNA and develops immune-mediated kidney disease treatments.
$36.00
After hours−0.22 (−0.61%)
At close$36.22(+5.75%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 108.36% | 78.09M shares | |
|---|---|---|---|
| 234 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 13.40% | 9.66M shares | |
| 13 holders · as of Sep 17, 2026 | |||
| Adds to | 121.76% | ||
72.06M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 121.76%; nothing is left for Other.
13F, as of Jun 30, 2026
234 holders · 78.09M shares · 33 new positions · 133 increased · 68 reduced · 37 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.75M | 7.98% | +659.7K | Aug 7, 2026 |
| Avoro Capital Advisors LLC | 5.72M | 7.94% | −165.0K | Aug 14, 2026 |
| State Street Corp | 4.15M | 5.76% | +785.1K | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 4.01M | 5.57% | −561.1K | Aug 14, 2026 |
| Deep Track Capital, LP | 4.00M | 5.55% | −106.1K | Aug 14, 2026 |
| Deerfield Management Company, L.P. (Series C) | 3.92M | 5.43% | +194.3K | Aug 14, 2026 |
| Kynam Capital Management, LP | 2.89M | 4.01% | −508.2K | Aug 14, 2026 |
| Morgan Stanley | 2.80M | 3.88% | +2.43M | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 8.90% | 5.61M | 13G | Feb 14, 2025 |
| T. Rowe Price Associates, Inc. | 6.40% | 4.57M | 13G | May 15, 2026 |
| State Street Corporation | 5.80% | 4.15M | 13G | Aug 7, 2026 |
| Deep Track Capital, LP | 5.50% | 3.92M | 13G | Mar 11, 2026 |
| Kynam Capital Management, LP | 5.37% | 3.43M | 13G | Aug 14, 2025 |
| Deerfield Mgmt, L.P. | 5.25% | 3.35M | 13G | Jun 11, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 15, 2026 | Marshall Fordycedirector, officer: PRESIDENT AND CEO | Sale | 18,500 | $37.00 | 235,244 |
| Sep 2, 2026 | Marshall Fordycedirector, officer: PRESIDENT AND CEO | Sale | 18,500 | $35.12 | 235,244 |
| May 12, 2026 | Marshall Fordycedirector, officer: PRESIDENT AND CEO | Sale · 2 lots | 18,500 | $36.74 | 235,244 |
| Jun 23, 2026 | Marshall Fordycedirector, officer: PRESIDENT AND CEO | Sale · 2 lots | 18,500 | $37.93 | 235,244 |
| Jul 7, 2026 | Marshall Fordycedirector, officer: PRESIDENT AND CEO | Sale · 4 lots | 46,250 | $42.30 | 235,244 |
| Apr 14, 2026 | Marshall Fordycedirector, officer: PRESIDENT AND CEO | Sale · 3 lots | 22,951 | $44.05 | 235,244 |
| Feb 23, 2026 | Laurence Matthew Skeltonofficer: Chief Commercial Officer | Sale | 1,582 | $41.98 | 64,218 |
| Feb 23, 2026 | William D. Turnerofficer: Chief Regulatory Officer | Sale | 2,187 | $41.98 | 45,313 |
| Feb 23, 2026 | David Lee Johnsonofficer: Chief Operating Officer | Sale | 2,579 | $41.98 | 45,727 |
| Feb 23, 2026 | Marshall Fordycedirector, officer: PRESIDENT AND CEO | Sale | 16,925 | $41.98 | 257,163 |
House and Senate disclosures
Not reported.